Eli Lilly and Co.The manufacturer or Zero And Mounjaro announced the success on Thursday of its phase 3 clinical trial for a GLP-1 pill once a day, an oral form of the medication of great success used for diabetes and Weight loss.
The drug trial, orforglipron, measured its effectiveness and safety in adults with type 2 diabetes compared to a placebo. He found that the pill reduced A1C, a blood level used to diagnose diabetes, on an average or 1.3% to 1.6%, in different doses, after 40 weeks.
Participants who take the highest dose also lost an average or 16 pounds.
“Since the participants had not yet reached a weight plateau at the time the study ended, it seems that the total weight reduction was not yet attacked,” said the company in a press release. It did not include information about the demography of the people who participated in the trial.
The most commonly informed announceable effects were gastrointestinal problems from mild to moderate, which include diarrhea, nausea, indigestion, constipation and vomiting.
The pill, which would sacrifice an alternative to injections, is the first oral LPG-1 of small molecule in a phase 3 test, the company said.
Eli Lilly says he plans to present orforgripron to the United States Food and Medicines Administration for approval as a treatment of type 2 diabetes in 2026. For weight control, he plans to present the medicine to the world regulatory agencies at the end of this year.
“If approved, the company trusts its ability to launch orforgripron worldwide without supply restrictions,” said the press release. “This would promise Lilly’s mission to reduce chronic diseases such as type 2 diabetes, which is expected to affect about 760 million adults by 2050”.
